This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2000;283:1131.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved bexarotene (Targretin; Ligand Pharmaceuticals Inc, San Diego) for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients who have not responded to at least one prior systemic treatment. Bexarotene is a member of a subclass of retinoids that selectively activate retinoid X receptors, which when activated function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene, a member of a class of retinoids associated with birth defects in humans, must not be given to a pregnant woman who is, or intends to become, pregnant.

Bexarotene was evaluated in 152 patients with advanced and early-stage CTCL in two studies. Of the 102 patients with disease refractory to at least one prior systemic therapy, 90 had advanced disease and had received a median of five prior systemic, irradiation, and/or topical therapies. Twelve patients with early disease had received . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Topical Targretin and Intralesional Interferon Alfa for Cutaneous Lymphoma of the Scalp
Trent et al.
Arch Dermatol 2002;138:1421-1423.
FULL TEXT  

Induction of Apoptosis by Bexarotene in Cutaneous T-Cell Lymphoma Cells: Relevance to Mechanism of Therapeutic Action
Zhang et al.
Clin. Cancer Res. 2002;8:1234-1240.
ABSTRACT | FULL TEXT